The Power List is our chance to put the pharmaceutical and drug development industry’s inspirational thought leaders, opinion shapers and unsung heroes in the spotlight. We’re relying on you to ensure that the breadth of perspectives is as wide as possible!

Spiraling Towards an Answer

Researchers capture the interactions of antibodies with the parasite responsible for malaria for the first time

Maryam Mahdi
|
01/15/2019

What begins as a tiny bite from a mosquito, driven by its thirst for blood, can transmit an illness that causes nearly half a million deaths every year: malaria. And though $2.7 billion was spent in an effort to control and eliminate the number of cases of malaria worldwide, risk of transmission remains high, with case incidence steadily rising in the Americas, South-East Asia, Western Pacific and African regions (1).

The battle against malaria has been long and arduous for scientists and healthcare professionals on the front line. The sheer structural complexity of Plasmodium falciparum – the parasite responsible for causing the deadliest form of malaria – makes it a particularly difficult disease to treat.

RTS,S is a malaria vaccine that has demonstrated protective effects in both children and infants – it received a positive opinion from the European regulatory authorities in July and will be rolled out through a pilot introduction in areas of three African countries beginning in 2019. Scientists at the Scripps Research Institute and PATH’s Malaria Vaccine Initiative have been conducting a cryo-electron microscopy (cryo-EM) investigation, as part of an international effort to further improve the vaccine. Specifically, the researchers looked at antibodies isolated from people who received the RTS,S vaccine and revealed, for the first time, how they interact with P. falciparum by locking the circumsporoite protein on the parasite surface into a spiral-like conformation (2). “We were absolutely delighted to see the first images. No-one could have predicted that we would see a structure like this,” says Ian Wilson, Professor at Scripps Research and co-corresponding author of the study.

Enjoy our FREE content!

Log in or register to read this article in full and gain access to
The Medicine Maker’s entire content archive. It’s FREE and always will be!